Condition: Melanoma · Lymphoma · Solid Tumor · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrollment of participants with solid tumors and participants 6 months to under 12 years old with melanoma were closed. With Amendment 13, enrollment was closed for participants with relapsed refractory classical Hodgkin lymphoma (rrCHL), microsatellite instabilty-high (MSI-H) solid tumors, tumor-mutational burden-high (TMB-H) solid tumors, and participants 12 years old to \<18 years old with advanced melanoma.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Call for Information (Investigational Site 0019) | Aurora, Colorado, United States | Recruiting |
| Call for Information (Investigational Site 0024) | Chicago, Illinois, United States | Recruiting |
| Call for Information (Investigational Site 0026) | Boston, Massachusetts, United States | Recruiting |
| Call for Information (Investigational Site 0031) | New York, New York, United States | Recruiting |
| Call for Information (Investigational Site 0070) | Fargo, North Dakota, United States | Recruiting |
| Call for Information (Investigational Site 0071) | Sioux Falls, South Dakota, United States | Recruiting |
| Call for Information (Investigational Site 0054) | Dallas, Texas, United States | Recruiting |
| MSD Brasil | São Paulo, Brazil | Recruiting |
| MSD France | Paris, France | Recruiting |
| MSD Sharp & Dohme GmbH | München, Germany | Recruiting |
| Merck Sharp & Dohme Co. Ltd. | Hod HaSharon, Israel | Recruiting |
| MSD Italia S.r.l. | Rome, Italy | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02332668